In simple terms, BioMarin Pharmaceutical Inc. has 1.821 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.000% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.000%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.000%. This tells us they're good at keeping money after all costs.
Return on Investments
The company's asset efficiency, represented by a robust 0.000% return, is a testament to BioMarin Pharmaceutical Inc.'s adeptness in optimizing resource deployment. BioMarin Pharmaceutical Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.000%. Furthermore, the proficiency of BioMarin Pharmaceutical Inc. in capital utilization is underscored by a remarkable 0.000% return on capital employed.
Stock Prices
BioMarin Pharmaceutical Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $93.35, while its low point bottomed out at $92.18. This variance in figures offers investors a lucid insight into the roller-coaster ride that is BioMarin Pharmaceutical Inc.'s stock market.
Company general description and statistics
Sector: Healthcare
Industry: Pharmaceuticals, Biotechnology & Life Sciences
CEO:Mr. Jean-Jacques Bienaime M.B.A., MBA
Full-time employees:3082
City:San Rafael
Address:770 Lindaro Street
IPO:2018-01-29
CIK:
Website:
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
